American journal of stem cells最新文献

{"title":"Bone marrow stem cell therapy in heart failure patients with low ejection fraction: a systematic review.","authors":"Azin Alizadehasl, Seyedeh Fatemeh Hosseini Jebelli, Yasamin Afsari Zonooz, Azam Yalameh Aliabadi, Maryam Mohseni Salehi, Golnar Mortaz Hejri, Sarah Forati, Hoda Hakimian","doi":"10.62347/YKPS8756","DOIUrl":"10.62347/YKPS8756","url":null,"abstract":"<p><p>The association of bone marrow stem cells (BMSCs) with cardiac function outcomes and treatment outcomes in heart failure (HF) patients with low ejection fraction (EF) has been heterogeneous across studies. This systematic review aimed to investigate the effect of BMSCs on functional, clinical, quality of life, and major adverse cardiovascular events (MACE) outcomes in HF patients with low EF. PubMed, Scopus, Clinicaltrial.gov, Cochrane Library, Google Scholar, and Web and reference databases were searched for articles that examined the effect of BMSCs therapy on improving cardiac outcomes in patients with low EF, from 2000 to 2024. Differences in left ventricular ejection fraction (LVEF), MACE, echocardiographic indices (left ventricular ejection fraction (LVEF), left ventricular end-diastolic volume (LVEDV), and left ventricular end-systolic volume (LVESV)), 6-min walk test (6-MWT), New York Heart Association (NYHA) class and immunologic responses were defined as outcomes. Low EF was defined as an EF <45%. Finally, 14 RCTs involving 710 HF patients with low EF were included. BMSCs transplantation was associated with improvements in echocardiographic parameters, EF rate, and NYHA class in most studies (9 of 14) compared to the control group, regardless of the time of outcome assessment (3 or 6 months). It also significantly improved the 6-MWT in most studies. Improvements in parameters and functional outcomes were similar at both evaluation periods, 6 and 12 months. The BMSCs transplantation was not significantly associated with the incidence of MACE and immunological responses. The results of this systematic review supported the positive role of BMSCs transplantation in improving echocardiographic parameters, EF rate, NYHA class, and 6-MWT in HF patients with low EF. BMSCs transplantation was not significantly associated with the incidence of MACE and immunological responses.</p>","PeriodicalId":7657,"journal":{"name":"American journal of stem cells","volume":"14 3","pages":"146-155"},"PeriodicalIF":1.9,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12444438/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145111881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of decitabine on human induced pluripotent stem cells (hiPSCs) derived CD34⁺ cells expansion and the megakaryocytes generation and maturation.","authors":"Yanfeng Liu, Hongyan Zhang, Yanxin Li, Chuanli Zhao","doi":"10.62347/IRBE1598","DOIUrl":"10.62347/IRBE1598","url":null,"abstract":"<p><strong>Background: </strong>Epigenetic modifiers play an important role in regulating the fate of hematopoietic stem cells (HSCs). The chromatin-modifying agents (CMA) have previously been shown to expand HSCs from cord blood (CB) and bone marrow (BM) CD34⁺ cells. Meanwhile, DNA methylation maintains persistent cellular memories and is thought to be the primary epigenetic barrier to reprogramming. The DNA hypomethylation drug decitabine is one of the CMA that could alter gene expression and HSC self-renewal. It has been reported that decitabine could promote platelets generation in ITP patients.</p><p><strong>Objective: </strong>It's unknown if decitabine could affect CD34⁺ cells and megakaryocytes generation and maturation from human induced pluripotent stem cells (hiPSCs).</p><p><strong>Methods: </strong>We utilized serum free, exon free and feeder free differentiation system to generate CD34⁺ from hiPSCs and induced them differentiation into megakaryocytes. Different concentrations of decitabine were added at different stages and analyzed these cells by RT-PCR, flow cytometry analysis, cell counting and other regular experimental methods.</p><p><strong>Results: </strong>The proliferation and function of CD34⁺ cells in vitro were significantly suspended after exposure to decitabine. Low concentration of decitabine could maintain the CD34⁺ function. In addition, we found that decitabine did not have any effect on the megakaryocyte generation, but it prevented megakaryocyte maturation. The DNA methyltransferases (<i>DNMTs</i>) changed a lot not only in CD34⁺ stage but also in the megakaryocyte generation and maturation due to decitabine addition.</p><p><strong>Conclusions: </strong>These results suggested that the effect of decitabine on CD34⁺ cells from hiPSCs was very different from CB, PB and BM CD34⁺ cells and the epigenetic changes may play an important role in the CD34⁺ expansion and megakaryocytes maturation. It may provide a potential mechanism of studying hiPSCs derived HSCs and megakaryocytes maturation in the future.</p>","PeriodicalId":7657,"journal":{"name":"American journal of stem cells","volume":"14 3","pages":"156-169"},"PeriodicalIF":1.9,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12444434/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145111906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epigenetic crosstalk between stem cells and tumors: mechanisms and emerging perspectives.","authors":"Wenli Zhou, Xuehai Liu, Zhaoyu Li, Binkui Jia, Xilin Lei, Kai Sun, Pengfei Yang, Shiye He, Di Wang, Haoling Zhang, Sinong Wang","doi":"10.62347/GQZH3508","DOIUrl":"10.62347/GQZH3508","url":null,"abstract":"<p><p>Stem cells possess self-renewal and multipotent differentiation capabilities, exhibiting broad applications in regenerative medicine and tissue homeostasis maintenance. Their fate regulation relies heavily on precise epigenetic mechanisms. Cancer stem cells (CSCs), as key drivers of tumor heterogeneity, recurrence, and drug resistance, share extensive epigenetic features with normal stem cells, forming a complex and dynamic regulatory network. Mechanisms including DNA methylation, histone modification, chromatin remodeling, and ncRNAs collectively sustain stem cell pluripotency and tumor stemness, while aberrant epigenetic alterations serve as core drivers of tumor initiation and progression. In recent years, with the advent of single-cell omics and CRISPR-dCas9 epigenetic editing technologies, epigenetic \"crosstalk\" between stem cells and tumor cells has been progressively uncovered, especially the multidimensional epigenetic reprogramming induced by the tumor microenvironment (TME) that promotes CSC traits and drug resistance. This review systematically summarizes the epigenetic regulatory mechanisms of stem cells, epigenetic abnormalities in tumors, their interactions, and translational potential in therapeutic strategies, focusing on frontier topics such as reversible epigenetic plasticity, metabolic-epigenetic interplay, and liquid biopsy epigenetic biomarkers. Looking forward, artificial intelligence (AI) and big data analysis are expected to deepen the understanding of epigenetic heterogeneity, driving integrative innovations in precision medicine and regenerative interventions. Comprehensive understanding of the epigenetic crosstalk between stem cells and tumors will provide solid theoretical support and technical pathways for CSC-targeted therapies, epigenetic drug development, and stem cell fate manipulation.</p>","PeriodicalId":7657,"journal":{"name":"American journal of stem cells","volume":"14 3","pages":"98-133"},"PeriodicalIF":1.9,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12444435/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145111850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhanced differentiation capacity of parthenogenetic embryonic stem cells via incorporation of non-growing oocyte genomes in mouse.","authors":"Hua Shao, Jie Cao, Ronghua Lu","doi":"10.62347/YZAN4747","DOIUrl":"10.62347/YZAN4747","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate the in vivo developmental and therapeutic potential of a novel parthenogenetic embryonic stem cell line (NF-pES), which contains genomes from both non-growing and grown oocytes.</p><p><strong>Methods: </strong>NF-pES cells were injected into mouse blastocysts to generate chimeric mice, and their contribution to various tissues was assessed. Skeletal muscle differentiation potential was examined through teratoma assays and analysis of muscle tissue in chimeric mice. For therapeutic assessment, a skeletal muscle injury model was established by cardiotoxin and irradiation treatment of the tibialis anterior muscle. NF-pES-derived precursor cells, obtained through in vitro induction and differentiation, were transplanted into the injured muscle.</p><p><strong>Results: </strong>Notably, NF-pES cells contributed extensively to multiple somatic lineages in chimeric mice, with high levels of chimerism observed in the heart (83.36%) and bone marrow (50.44%). These levels are comparable to those achieved with embryonic stem cells derived from fertilized embryos. Importantly, NF-pES cells demonstrated robust myogenic differentiation capacity, as evidenced by their contribution to skeletal muscle tissues in both teratoma formation assays and in vivo chimeric muscle integration. Following in vitro induction, NF-pES-derived precursors were transplanted into the injured tibialis anterior muscle of recipient mice to assess their regenerative potential in vivo. One month after transplantation, immunohistochemical analysis confirmed the successful engraftment of donor-derived cells within the host muscle tissue. These donor-derived cells expressed markers of terminal myogenic differentiation and were incorporated into mature skeletal muscle fibers.</p><p><strong>Conclusions: </strong>NF-pES cells exhibit strong developmental capacity and therapeutic potential for skeletal muscle regeneration, suggesting their value in future regenerative medicine applications.</p>","PeriodicalId":7657,"journal":{"name":"American journal of stem cells","volume":"14 3","pages":"134-145"},"PeriodicalIF":1.9,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12444436/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145111901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The predawn dilemma in adeno-associated virus-based gene therapies for hereditary deafness.","authors":"Jiao Zhou, Di Deng, Chunmei Gan, Jintao Du, Yu Zhao","doi":"10.62347/FESN5062","DOIUrl":"10.62347/FESN5062","url":null,"abstract":"<p><p>Hearing loss is a prevalent organ-specific disorder affecting individuals throughout their lifespan, with over 466 million cases reported globally. The conditions can be classified into two broad categories: hereditary and nonhereditary. HHL, caused by genetic mutations or chromosomal abnormalities, can be divided into nonsyndromic (NSHL) and syndromic (SHL) subtypes. NSHL presents as isolated auditory impairment without systemic manifestations, whereas SHL involves concurrent dysfunction in other organ systems. Nonhereditary hearing loss typically results from infections, ototoxic drugs, noise exposure, trauma, or age-related degeneration. Current clinical interventions focus on symptom management through hearing aids and cochlear implants, as no curative treatment exists for genetic forms. Recent studies have shown the therapeutic potential of gene therapy in animal models of genetic deafness, although clinical translation faces challenges, including viral vector safety, transfection efficiency, and target specificity. This systematic review synthesizes current progress in gene therapy for HHL and evaluates barriers to clinical implementation, offering insights for future translational studies.</p>","PeriodicalId":7657,"journal":{"name":"American journal of stem cells","volume":"14 3","pages":"73-97"},"PeriodicalIF":1.9,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12444437/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145111869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Platinum chemotherapeutic-induced oxidative stress affects the transcriptional response of DNA repair genes in murine mesenchymal stem cells.","authors":"Sehrish Jabeen, Yasir Raza, Sumreen Begum, Saira Yahya, Arif Ali Chishti, Tashmeem Razzaki","doi":"10.62347/TICZ7344","DOIUrl":"10.62347/TICZ7344","url":null,"abstract":"<p><p>Cisplatin and oxaliplatin are among the most extensively used anti-cancer drugs in the treatment of various types of cancer. However, the cytotoxicity associated with these drugs in normal and adult stem cells is a major concern.</p><p><strong>Objectives: </strong>This study aimed to determine the oxidative stress induced by platinum drugs in murine mesenchymal stem cells (mMSCs).</p><p><strong>Methods: </strong>mMSCs were cultured and treated with cisplatin and oxaliplatin concentrations (5 μM, 15 μM, and 25 μM/L) for 1, 4, 24, 48, and 72 hours. Morphological changes and viability of cells were observed. Oxidative stress was assessed by the expression of 8-Hydroxy-2'-deoxyguanosine (8-OHdG). Necroptosis was determined by Acridine Orange/Ethidium Bromide (AO/EB) staining. Moreover, mRNA levels of DNA repair genes, particularly genes involved in mismatch repair (MMR), including MLH3, MSH2, MLH1, MSH6, and PMS2, and nucleotide excision repair (NER) pathways, such as ERCC1 were measured using Taq-Man Quantitative Real-Time Polymerase Chain Reaction (TaqMan-qRT-PCR).</p><p><strong>Results: </strong>The proliferation and morphology of mMSCs were noticeably influenced by cisplatin and oxaliplatin at 25 μM, compared to 5 μM and 15 μM by 72 hours. 8OHdG positive and necroptotic cells were significantly (<i>P</i> < 0.001) high from 24 to 72 hours among 25 μM drug-treated mMSCs. The concentration and temporal oxidative stress generated in mMSCs by cisplatin and oxaliplatin disturbed the expression of DNA repair genes at the mRNA level (<i>P</i> < 0.001). Cisplatin remarkably upregulated the expression of MLH1 and PMS2 (≥ 3.0-fold) at 24 hours, while it downregulated MSH2, MLH1, MSH6, and PMS2 (≤ 0.5-fold) at 72 hours. However, oxaliplatin noticeably caused the upregulation of MLH3 and ERCC1 expression (≥ 3.0-fold) at 24-48 hours, and downregulation of MSH2, MLH1, MSH6, PMS2, and ERCC1 (≤ 0.5-fold) at 72 hours.</p><p><strong>Conclusions: </strong>This suggests that adult stem cells in tissues and organs are highly vulnerable to platinum drugs during cancer treatment. Additional studies on localized treatments may help to prevent adverse effects on normal cells.</p>","PeriodicalId":7657,"journal":{"name":"American journal of stem cells","volume":"14 2","pages":"34-52"},"PeriodicalIF":1.5,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12267125/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144673718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Melanocyte dysfunctions: future and promise of stem cells.","authors":"Sharique A Ali, Gulafsha Kassab, Tasneem Husain","doi":"10.62347/EOIC7075","DOIUrl":"10.62347/EOIC7075","url":null,"abstract":"<p><p>Human melanocytes (MCs) and melanocyte stem cells (McSCs) are integral to skin pigmentation and appendage pigmentation, originating embryonically from neural crest cells. In adult skin, McSCs residing in the epidermis sustain the continuous regeneration of functional melanocytes, a process vital for skin homeostasis and repair. Advances in McSC research have unravelled their pivotal roles in combating disorders such as vitiligo, hair greying, impaired wound healing, and melanoma. Previous studies have significantly advanced our knowledge of the cellular and molecular characteristics of this unique stem cell population. However, a comprehensive understanding of their characteristics in melanocyte dysfunctions leading to conditions like vitiligo is still lacking. Dysfunction or depletion of McSCs is linked to these conditions, highlighting their significance in maintaining skin health. Cutting-edge technologies like single-cell RNA sequencing, spatial transcriptomics, gene editing, and whole-genome sequencing have deepened our understanding of McSC biology and their regulatory microenvironment. This review delves into the latest discoveries, offering a comprehensive perspective on McSCs and their therapeutic potential. By identifying specific molecular signals and crosstalk mechanisms, McSC research opens avenues for regenerative medicine applications, including skin repigmentation, tissue repair, and cancer treatment. The field's progression sets the stage for transformative breakthroughs in skin regeneration and broader regenerative therapies.</p>","PeriodicalId":7657,"journal":{"name":"American journal of stem cells","volume":"14 2","pages":"25-33"},"PeriodicalIF":1.5,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12267124/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144673716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mesenchymal stem cells in injury repair of vital organs: from mechanism to clinical application.","authors":"Liwei Bao, Zihan Wang, Li Li, Shengbin Tang, Guang Zhao, Huihui Zhang, Xia Zhang","doi":"10.62347/YGXA7976","DOIUrl":"10.62347/YGXA7976","url":null,"abstract":"<p><p>Mesenchymal stem cells (MSCs) are a type of pluripotent stem cells originating from the mesoderm, known for their capability to differentiate into various specific tissue cell types and fulfill corresponding physiological roles. Furthermore, MSCs are essential in modulating the tissue microenvironment through the release of soluble factors that can modify the local inflammatory conditions of injured tissues. As a result, MSCs show considerable promise for therapeutic use in a range of traumatic scenarios, including but not limited to liver damage, myocardial infarction, neurological conditions, lung trauma, kidney injuries, and disorders affecting the female reproductive system. They play a key role in alleviating cell apoptosis, sustaining cell survival, encouraging proliferation, enhancing the inflammatory milieu, minimizing tissue fibrosis, and supporting vascular regeneration. These mechanisms are crucial for controlling excessive and persistent inflammatory reactions that arise after organ injury, which may lead to cell death and hindered blood circulation, ultimately causing fibrosis and weakened organ functionality. Additionally, MSCs are gradually being incorporated into clinical settings, where careful considerations regarding methods of administration, dosing, safety, and effectiveness are vital for achieving optimal clinical results. This review provides an overview of the mechanisms by which mesenchymal stem cells aid in the repair of major bodily organs. We also examine their current status, obstacles, and pertinent issues concerning clinical applications.</p>","PeriodicalId":7657,"journal":{"name":"American journal of stem cells","volume":"14 2","pages":"53-72"},"PeriodicalIF":1.5,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12267123/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144673717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Human umbilical cord Wharton's jelly mesenchymal cell medium progress the wound healing via cytokines and growth factors expressions.","authors":"Tahereh Ebrahimi, Vahideh Tarhriz, Haleh Forouhandeh, Fatemeh Sadat Shariati, Ali Sahraeian Jahromi, Mohammad Hosein Hadian Tabarestani, Hossein Fathollahzadeh, Masoud Delashoub","doi":"10.62347/AMSW4025","DOIUrl":"10.62347/AMSW4025","url":null,"abstract":"<p><strong>Objective: </strong>Conditioned medium of umbilical cord mesenchymal cells is a rich environment in various growth factors and cytokines, the use of which causes self-improvement and self-renewal in damaged tissues.</p><p><strong>Methods: </strong>Therefore, we investigated the effect of Wharton's umbilical cord mesenchymal cells on cytokines, growth factors expression, and skin wound healing in diabetic rats. Rats were divided into two groups of ten. In the treated diabetic group, 1 ml of conditioned medium was used intradermally, and in the diabetic control group, the same amount of physiological serum was used. The tissue samples were evaluated for histological studies. The expression level of inflammatory/anti-inflammatory cytokines and growth factors was investigated using RT-PCR and western blotting analysis.</p><p><strong>Results: </strong>Our results showed that wound healing increased in the diabetic rat group with a pleasant environment compared to the control group. It was also found in molecular studies that the expression of anti-inflammatory cytokines and growth factors was significantly increased in the treated samples compared to the control group. In addition, a significant decrease in TGF-β expression as an important inflammatory cytokine observed compared to the control group.</p><p><strong>Conclusions: </strong>The use of the conditioned environment of Wharton's jelly mesenchymal cells of the human umbilical cord improves the process of wound healing in terms of tissue and also increases the expression of the critical anti-inflammatory cytokines and growth factors. It can be considered a novel approach in wound healing treatment.</p>","PeriodicalId":7657,"journal":{"name":"American journal of stem cells","volume":"14 1","pages":"14-24"},"PeriodicalIF":1.5,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12089826/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144118549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating nanoparticle's utilization in stem cell therapy for neurological disorders.","authors":"Sadia Aziz, Sundus Anbreen, Shaheen Shahzad, Muhammad Saad Ahmed, Vivek Sharma, Jing Yang, Liaqat Ali","doi":"10.62347/YGYM4976","DOIUrl":"10.62347/YGYM4976","url":null,"abstract":"<p><p>Stem cell therapy is a promising area of regenerative medicine, offering potential treatments for various life-threatening disorders. Stem cells are classified based on their differentiation potential into totipotent, pluripotent, and multipotent stem cells. Among them, mesenchymal stem cells (MSCs) are widely used in regenerative medicine due to their tissue regeneration capabilities and ability to differentiate into multiple cell types. Stem cells are being explored for treating neurodegenerative disorders like Parkinson's, Alzheimer's, Huntington's, and amyotrophic lateral sclerosis (ALS). These conditions result from progressive neuronal degeneration, leading to irreversible damage. Challenges such as cell survival, immune rejection, tumor formation, and ethical concerns related to embryonic stem cells need to be addressed. Nanotechnology is emerging as a tool for enhancing stem cell therapy, improving targeted delivery and effectiveness. Nanoparticles possess the ability to create microenvironments as substrates, facilitate targeted administration, and enable real-time, precise imaging of stem cells. This review explores the integration of stem cells and nanotechnology as regenerative medicine tool for neurodegenerative disease treatment, analyzing current strategies and therapeutic approaches. Integrating nanotechnology with stem cell therapy may significantly improve targeted delivery and enhance regenerative outcomes for neurodegenerative disorders.</p>","PeriodicalId":7657,"journal":{"name":"American journal of stem cells","volume":"14 1","pages":"1-13"},"PeriodicalIF":1.5,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12089827/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144118397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}